NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

PURPOSE: Veliparib is a PARP inhibitor (PARPi) with activity in BRCA 1/2/PALB2-deficient tumors. Preclinical observations reveal topoisomerase inhibitors like irinotecan are synergistic with PARPi irrespective of homologous recombination deficiency (HRD), potentially expanding the role for PARPi. EX...

Descripción completa

Detalles Bibliográficos
Autores principales: Cecchini, Michael, Walther, Zenta, Wei, Wei, Hafez, Navid, Pilat, Mary Jo, Boerner, Scott A., Durecki, Diane E., Eder, Joseph P., Schalper, Kurt A., Chen, Alice P., LoRusso, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292219/
https://www.ncbi.nlm.nih.gov/pubmed/37377610
http://dx.doi.org/10.1158/2767-9764.CRC-22-0485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292219/
https://www.ncbi.nlm.nih.gov/pubmed/37377610
http://dx.doi.org/10.1158/2767-9764.CRC-22-0485

Ejemplares similares